EcoDrugPlus

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSSVLG00005007461
Gene Symbol: GUCY1A1
1 Cross references
202 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSSVLG00005020104
Gene Symbol: GUCY1A2
1 Cross references
201 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSSVLG00005007566
Gene Symbol: GUCY1B1
1 Cross references
209 Possible Orthologues:

Heat Shock Protein 90 Alpha Family Class A Member 1

Ensembl ID : ENSSVLG00005015100
Gene Symbol: HSP90AA1
1 Cross references
200 Possible Orthologues:

Heat Shock Protein 90 Alpha Family Class B Member 1

Ensembl ID : ENSSVLG00005004982
Gene Symbol: HSP90AB1
1 Cross references
205 Possible Orthologues:

Histamine Receptor H1

Ensembl ID : ENSSVLG00005021749
Gene Symbol: HRH1
1 Cross references
186 Possible Orthologues:

Histamine Receptor H2

Ensembl ID : ENSSVLG00005011848
Gene Symbol: HRH2
1 Cross references
249 Possible Orthologues:

Histamine Receptor H3

Ensembl ID : ENSSVLG00005003009
Gene Symbol: HRH3
1 Cross references
117 Possible Orthologues:

Histamine Receptor H4

Ensembl ID : ENSSVLG00005009808
Gene Symbol: HRH4
1 Cross references
105 Possible Orthologues:

Histone Deacetylase 1

Ensembl ID : ENSSVLG00005021166
Gene Symbol: HDAC1
1 Cross references
266 Possible Orthologues:

Histone Deacetylase 10

Ensembl ID : ENSSVLG00005008461
Gene Symbol: HDAC10
1 Cross references
181 Possible Orthologues:

Histone Deacetylase 11

Ensembl ID : ENSSVLG00005015239
Gene Symbol: HDAC11
1 Cross references
197 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).